Irvine, United States
Bioniz, LLC, a biotechnology company founded in 2009 and headquartered in Irvine, California, is making significant strides in the realm of drug development. With a focus on improving treatment options for autoimmune diseases and certain cancers, Bioniz employs innovative small peptides and molecules to pioneer advancements in healthcare.
The company's mission is firmly rooted in advancing its leading technology through proof-of-concept and preclinical studies. Bioniz aims to partner strategically for clinical trials to achieve regulatory approval and commercialization successfully. They maintain a strong research ethos, emphasizing integrity and responsibility to public health and investors.
In its last funding round, Bioniz secured a $13.00M Series A investment on 01 August 2016, backed by notable investors including Signatures Capital, Cota Capital, Takeda Pharma, and David Pyott. This investment underlines the growing confidence in Bioniz's potential to impact the biotechnology and health care sectors significantly.
